Toradol im injection, iv injection
TORADOL, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. It is NOT indicated for minor or chronic painful conditions. TORADOL is a potent NSAID analgesic, and its administration carries many risks. The resulting NSAID-related adverse events can be serious in certain patients for whom TORADOL is indicated, especially when the drug is used inappropriately. Increasing the dose of TORADOL beyond the label recommendations will not provide better efficacy but will result in increasing the risk of developing serious adverse events.
·TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
·TORADOL is CONTRAINDICATED in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion (see WARNINGS ).
RISK OF BLEEDING
·TORADOL inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS ).
·TORADOL is CONTRAINDICATED as prophylactic analgesic before any major surgery and is CONTRAINDICATED intraoperatively when hemostasis is critical because of the increased risk of bleeding.
·Hypersensitivity reactions, ranging from bronchospasm to anaphylactic shock, have occurred and appropriate counteractive measures must be available when administering the first dose of TORADOL IV/IM (see CONTRAINDICATIONS and WARNINGS ). TORADOL is CONTRAINDICATED in patients with previously demonstrated hypersensitivity to ketorolac tromethamine or allergic manifestations to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
INTRATHECAL OR EPIDURAL ADMINISTRATION
·TORADOL is CONTRAINDICATED for intrathecal or epidural administration due to its alcohol content.
LABOR, DELIVERY AND NURSING
·The use of TORADOL in labor and delivery is CONTRAINDICATED because it may adversely affect fetal circulation and inhibit uterine contractions.
·The use of TORADOL is CONTRAINDICATED in nursing mothers because of the potential adverse effects of prostaglandin-inhibiting drugs on neonates.
CONCOMITANT USE WITH NSAIDs
·TORADOL is CONTRAINDICATED in patients currently receiving ASA or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects.
DOSAGE AND ADMINISTRATION
·TORADOL ORAL is indicated only as continuation therapy to TORADOL IV/IM , and the combined duration of use of TORADOL IV/IM and TORADOL ORAL is not to exceed 5 days because of the increased risk of serious adverse events.
·The recommended total daily dose of TORADOL ORAL (maximum 40 mg) is significantly lower than for TORADOL IV/IM (maximum 120 mg) (see DOSAGE AND ADMINISTRATION and Transition from TORADOL IV/IM to TORADOL ORAL ).
·Dosage should be adjusted for patients 65 years or older, for patients under 50 kg (110 lbs) of body weight (see DOSAGE AND ADMINISTRATION ) and for patients with moderately elevated serum creatinine (see WARNINGS ). Doses of TORADOL IV/IM are not to exceed 60 mg (total dose per day) in these patients. TORADOL IV/IM is indicated as a single dose therapy in pediatric patients (see DOSAGE AND ADMINISTRATION ); not to exceed 30 mg for IM administration and 15 mg for IV administration.
TORADOL (ketorolac tromethamine) is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs). The chemical name for ketorolac tromethamine is (±)-5-benzoyl-2,3-dihydro-1 H -pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxy-methyl)-1,3-propanediol (1:1).
TORADOL is a racemix mixture of [-]S and [ + ]R ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. Ketorolac tromethamine has a pKa of 3.5 and an n-octanol/water partition coefficient of 0.26. The molecular weight of ketorolac tromethamine is 376.41. Its molecular formula is C 19 H 24 N 2 O 6 .
TORADOL is available for intravenous (IV) or intramuscular (IM) administration as: 15 mg in 1 mL (1.5%) and 30 mg in 1 mL (3%) in sterile solution; 60 mg in 2 mL (3%) of ketorolac tromethamine in sterile solution is available for IM administration only. The solutions contain 0.1% citric acid, 10% (w/v) alcohol, USP, and 6.68 mg, 4.35 mg and 8.70 mg, respectively, of sodium chloride in sterile water. The pH is adjusted with sodium hydroxide or hydrochloric acid, and the solutions are packaged with nitrogen. The sterile solutions are clear and slightly yellow in color.
TORADOL ORAL is available as round, white, film-coated, red-printed tablets. Each tablet contains 10 mg ketorolac tromethamine, the active ingredient, with added lactose, magnesium stearate and microcrystalline cellulose. The white film-coating contains hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide.
The tables are printed with red ink that includes FD&C Red #40 Aluminum lake as the colorant. There is a large T printed on both sides of the tablet, as well as the word TORADOL on one side, and the word ROCHE on the other.
Pharmacodynamics: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. Ketorolac tromethamine inhibits synthesis of prostaglandins and may be considered a peripherally acting analgesic. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
The peak analgesic effect of TORADOL occurs within 2 to 3 hours and is not statistically significantly different over the recommended dosage range of TORADOL. The greatest difference between large and small doses of TORADOL by either route is in the duration of analgesia.
Pharmacokinetics: Ketorolac tromethamine is a racemic mixture of [-]S- and [ + ]R-enantiomeric forms, with the S-form having analgesic activity.
Comparison of IV, IM and Oral Pharmacokinetics: The pharmacokinetics of ketorolac tromethamine, following IV, IM and oral doses of TORADOL, are compared in Table 1. In adults, the extent of bioavailability following administration of the ORAL and IM forms of TORADOL was equal to that following an IV bolus.
Linear Kinetics: In adults, following administration of single ORAL, IM or IV doses of TORADOL in the recommended dosage ranges, the clearance of the racemate does not change. This implies that the pharmacokinetics of ketorolac tromethamine in adults, following single or multiple IM, IV or recommended oral doses of TORADOL, are linear. At the higher recommended doses, there is a proportional increase in the concentrations of free and bound racemate.
Absorption: TORADOL is 100% absorbed after oral administration (see Table 1). Oral administration of TORADOL after a high-fat meal resulted in decreased peak and delayed time-to-peak concentrations of ketorolac tromethamine by about 1 hour. Antacids did not affect the extent of absorption.
Distribution: The mean apparent volume (V(beta)) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein bound (99%). Nevertheless, even plasma concentrations as high as 10 µg/mL will only occupy approximately 5% of the albumin binding sites. Thus, the unbound fraction for each enantiomer will be constant over the therapeutic range. A decrease in serum albumin, however, will result in increased free drug concentrations.
Metabolism: Ketorolac tromethamine is largely metabolized in the liver. The metabolic products are hydroxylated and conjugated forms of the parent drug. The products of metabolism, and some unchanged drug, are excreted in the urine.
Excretion: The principal route of elimination of ketorolac and its metabolites is renal. About 92% of a given dose is found in the urine, approximately 40% as metabolites and 60% as unchanged ketorolac. Approximately 6% of a dose is excreted in the feces. A single-dose study with 10 mg TORADOL (n=9) demonstrated that the S-enantiomer is cleared approximately two times faster than the R-enantiomer and that the clearance was independent of the route of administration. This means that the ratio of S/R plasma concentrations decreases with time after each dose. There is little or no inversion of the R- to S- form in humans. The clearance of the racemate in normal subjects, elderly individuals and in hepatically and renally impaired patients is outlined in Table 2 (see CLINICAL PHARMACOLOGY : Kinetics in Special Populations ).
The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer. In other studies, the half-life for the racemate has been reported to lie within the range of 5 to 6 hours.
Accumulation: TORADOL administered as an IV bolus every 6 hours for 5 days to healthy subjects (n=13), showed no significant difference in C max on Day 1 and Day 5. Trough levels averaged 0.29 µg/mL (SD ± 0.13) on Day 1 and 0.55 µg/mL (SD ± 0.23) on Day 6. Steady state was approached after the fourth dose.
Accumulation of ketorolac tromethamine has not been studied in special populations (geriatric, pediatric, renal failure or hepatic disease patients).
Kinetics in Special Populations
Geriatric Patients: Based on single-dose data only, the half-life of the ketorolac tromethamine racemate increased from 5 to 7 hours in the elderly (65 to 78 years) compared with young healthy volunteers (24 to 35 years) (see Table 2). There was little difference in the C max for the two groups (elderly, 2.52 µg/mL ± 0.77; young, 2.99 µg/mL ± 1.03) (see PRECAUTIONS : Geriatric Use ).
Pediatric Patients: Following a single intravenous bolus dose of 0.5 mg/kg in 10 children 4 to 8 years old, the half-life was 6 hours (range: 3.5 to 10 h), the average clearance was 0.042 L/hr/kg and the Vd was 0.26 L/kg (range: 0.19 to 0.44 L/kg). In a second study, following a single intravenous dose of 0.6 mg/kg in 24 children 3 to 18 years old, C max was 4.3 ± 1.7 mcg/mL, T max was 10.25 ± 1.15 minutes, half-life was 3.8 ± 2.6 hours, Cl was 0.0678 L/hr/kg and Vd was 0.25 L/kg. The volume of distribution and clearance of ketorolac in pediatric patients was twice that observed in adult subjects (see Tables 1 and 2). There are no pharmacokinetic data available for TORADOL administration by the IM route in pediatric patients.
Renal Insufficiency: Based on single-dose data only, the mean half-life of ketorolac tromethamine in renally impaired patients is between 6 and 19 hours and is dependent on the extent of the impairment. There is poor correlation between creatinine clearance and total ketorolac tromethamine clearance in the elderly and populations with renal impairment (r=0.5).
In patients with renal disease, the AUC (infinity) of each enantiomer increased by approximately 100% compared with healthy volunteers. The volume of distribution doubles for the S-enantiomer and increases by 1/5th for the R-enantiomer. The increase in volume of distribution of ketorolac tromethamine implies an increase in unbound fraction.
The AUC (infinity) -ratio of the ketorolac tromethamine each enantiomers in healthy subjects and patients remained similar, indicating there was no selective excretion of either enantiomer in patients compared to healthy subjects (see WARNINGS : Renal Effects and Table 2).
Hepatic Insufficiency: There was no significant difference in estimates of half-life, AUC (infinity) and C max in 7 patients with liver disease compared to healthy volunteers (see PRECAUTIONS : Hepatic Effects and Table 2).
Race: Pharmacokinetic differences due to race have not been identified.
IV Administration: In normal adult subjects (n=37), the total clearance of 30 mg IV-administered TORADOL was 0.030 (0.0.17-0.051) L/h/kg. The terminal half-life was 5.6 (4.0-7.9) hours. (See Kinetics in Special Populations for use of TORADOL IV in pediatric patients.)
Adult Patients: The analgesic efficacy of intramuscularly, intravenously and orally administered TORADOL was investigated in two postoperative pain models: general surgery (orthopedic, gynecologic and abdominal) and oral surgery (removal of impacted third molars). The studies were double-blind, single- and multiple-dose, parallel trial designs in patients with moderate to severe pain at baseline. TORADOL IV/IM was compared as follows: IM to meperidine or morphine administered intramuscularly and IV to morphine administered either directly IV or through a PCA (Patient-Controlled Analgesia) pump.
Short-Term Use (up to 5 days) Studies: In adults, the comparisons of intramuscular administration during the first hour, the onset of analgesic action was similar for TORADOL and the narcotics, but the duration of analgesia was longer with TORADOL than with the opioid comparators meperidine or morphine.
In a multidose, postoperative (general surgery) double-blind trial of TORADOL IM 30 mg versus morphine 6 and 12 mg IM, each drug given on an as needed basis for up to 5 days, the overall analgesic effect of TORADOL IM 30 mg was between that of morphine 6 and 12 mg. The majority of patients treated with either TORADOL or morphine were dosed for up to 3 days; a small percentage of patients received 5 days of dosing.
In clinical settings where perioperative morphine was allowed, TORADOL IV 30 mg, given once or twice as needed, provided analgesia comparable to morphine 4 mg IV once or twice as needed.
There was relatively limited experience with 5 consecutive days of TORADOL IV use in controlled clinical trials, as most patients were given the drug for 3 days or less. The adverse events seen with IV-administered TORADOL were similar to those observed with IM-administered TORADOL, as would be expected based on the similar pharmacokinetics and bioequivalence (AUC, clearance, plasma half-life) of IV and IM routes of TORADOL administration.
Pediatric Patients: The analgesic efficacy of single doses of TORADOL IV/IM has been demonstrated by showing a decrease in the need for supplemental narcotic in pediatric patients receiving ketorolac as compared to placebo. See discussion of these results under Clinical Studies With Concomitant Use of Opioids below.
Clinical Studies With Concomitant Use of Opioids
Adults Patients: Clinical studies in postoperative pain management have demonstrated that TORADOL IV/IM , when used in combination with opioids, significantly reduced opioid consumption. This combination may be useful in the subpopulation of patients especially prone to opioid-related complications. TORADOL and narcotics should not be administered in the same syringe.
In a postoperative study, where all patients received morphine by a PCA device, patients treated with TORADOL IV as fixed intermittent boluses (eg, 30 mg initial dose followed by 15 mg q3h), required significantly less morphine (26%) than the placebo group. Analgesia was significantly superior, at various postdosing pain assessment times, in the patients receiving TORADOL IV plus PCA morphine as compared to patients receiving PCA-administered morphine alone.
Pediatric Patients: TORADOL IM injection reduced the need for supplemental opioid (fentanyl) when a 1 mg/kg dose was administered immediately following tonsillectomy compared to saline controls (see WARNINGS : Hemorrhage ). In another study, when a single bolus dose of 0.9 mg/kg of TORADOL IV was given to pediatric patients ages 5 to 12 years, compared to saline, a reduction in supplemental opioid was needed following various surgical procedures. In a third study less supplemental morphine was needed in pediatric patients ages 8 to 16 years, who received a 0.8 mg/kg IV injection of TORADOL in conjunction with morphine following orthopedic surgical procedures, compared to morphine alone. In a study in pediatric patients ages 3 to 12 years, TORADOL IV demonstrated a slower onset of analgesia, but a longer duration of action compared to morphine. There is limited data available to support the use of multiple doses of TORADOL IV/IM in pediatric patients. There are also insufficient data available to support the use of TORADOL ORAL in pediatric patients.
Postmarketing Surveillance Study: A large postmarketing observational, nonrandomized study, involving approximately 10,000 patients receiving TORADOL, demonstrated that the risk of clinically serious gastrointestinal (GI) bleeding was dose-dependent (see Tables 3A and 3B). This was particularly true in elderly patients who received an average daily dose greater than 60 mg/day of TORADOL (see Table 3A).
Indications and Usage
Adult Patients: TORADOL is indicated for the short-term (</=5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with TORADOL IV/IM , and TORADOL ORAL is to be used only as continuation treatment, if necessary. Combined use of TORADOL IV/IM and TORADOL ORAL is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but TORADOL therapy is not to exceed 5 days.
Pediatric Patients: The safety and effectiveness of single doses of TORADOL IV/IM have been established in pediatric patients between the ages of 2 and 16 years. TORADOL, as a single injectable dose, has been shown to be effective in the management of moderately severe acute pain that requires analgesia at the opioid level, usually in the postoperative setting. There is limited data available to support the use of multiple doses of TORADOL in pediatric patients. Safety and effectiveness have not been established in pediatric patients below the age of 2 years. Use of TORADOL in pediatric patients is supported by evidence from adequate and well-controlled studies of TORADOL in adults with additional pharmacokinetic, efficacy and safety data on its use in pediatric patients available in the published literature (see CLINICAL PHARMACOLOGY : Clinical Studies , WARNINGS , and PRECAUTIONS ).
TORADOL IV/IM has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the TORADOL IV/IM dosage range with low doses of narcotics prn, unless otherwise contraindicated. TORADOL IV/IM and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION : Pharmaceutical Information for TORADOL IV/IM ).
CONTRAINDICATIONS (see also Boxed WARNING ):
·TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
·TORADOL is CONTRAINDICATED in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion (see WARNINGS for correction of volume depletion).
·TORADOL is CONTRAINDICATED in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage.
·The use of TORADOL is CONTRAINDICATED in nursing mothers because of the potential adverse events of prostaglandin-inhibiting drugs on neonates.
·TORADOL is CONTRAINDICATED in patients with pre-viously demonstrated hypersensitivity to ketorolac tromethamine, allergic manifestations to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
·TORADOL is CONTRAINDICATED as prophylactic analgesic before any major surgery and is CONTRAINDICATED intraoperatively when hemostasis is critical because of the increased risk of bleeding.
·TORADOL inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS ).
·TORADOL is CONTRAINDICATED in patients currently receiving ASA or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.
·TORADOL IV/IM is CONTRAINDICATED for neuraxial (epidural or intrathecal) administration due to its alcohol content.
·The concomitant use of TORADOL and probenecid is CONTRAINDICATED.
WARNINGS (see also Boxed WARNING ):
The combined use of TORADOL IV/IM and TORADOL ORAL is not to exceed 5 days in adults. Only single doses of TORADOL IV/IM are recommended for use in pediatric patients.
The most serious risks associated with TORADOL are:
- Gastrointestinal (GI) Effects - Risk of GI Ulceration, Bleeding, and Perforation: TORADOL is CONTRAINDICATED in patients with previously documented peptic ulcers and/or GI bleeding. Serious gastrointestinal toxicity, such as bleeding, ulceration and perforation, can occur at any time, with or without warning symptoms, in patients treated with TORADOL. Studies to date with NSAIDs have not identified any subset of patients not at risk of developing peptic ulceration and bleeding. Elderly or debilitated patients seem to tolerate ulceration or bleeding less well than other individuals, and most spontaneous reports of fatal GI events are in this population. Postmarketing experience with parenterally administered TORADOL suggests that there may be a greater risk of gastrointestinal ulcerations, bleeding and perforation in the elderly.
The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with, TORADOL. In a nonrandomized, in-hospital postmarketing surveillance study comparing parenteral TORADOL to parenteral opioids, higher rates of clinically serious GI bleeding were seen in adult patients <65 years of age who received an average total daily dose of more than 90 mg of TORADOL IV/IM per day (see CLINICAL PHARMACOLOGY : Postmarketing Surveillance Study ).
The same study showed that elderly (>/=65 years of age) and debilitated patients are more susceptible to gastrointestinal complications. A history of peptic ulcer disease was revealed as another risk factor that increases the possibility of developing serious gastrointestinal complications during TORADOL therapy (see Tables 3A and 3B).
- Hemorrhage: Because prostaglandins play an important role in hemostasis and NSAIDs affect platelet aggregation as well, use of TORADOL in patients who have coagulation disorders should be undertaken very cautiously, and those patients should be carefully monitored. Patients on therapeutic doses of anticoagulants (eg, heparin or dicumarol derivatives) have an increased risk of bleeding complications if given TORADOL concurrently; therefore, physicians should administer such concomitant therapy only extremely cautiously. The concurrent use of TORADOL and prophylactic low-dose heparin (2500 to 5000 units q12h), warfarin and dextrans have not been studied extensively, but may also be associated with an increased risk of bleeding. Until data from such studies are available, physicians should carefully weigh the benefits against the risks and use such concomitant therapy in these patients only extremely cautiously. In patients who receive anticoagulants for any reason, there is an increased risk of intramuscular hematoma formation from administered TORADOL IM (see PRECAUTIONS : Drug Interactions ). Patients receiving therapy that affects hemostasis should be monitored closely.
In postmarketing experience, postoperative hematomas and other signs of wound bleeding have been reported in association with the perioperative use of TORADOL IV/IM . Therefore, perioperative use of TORADOL should be avoided and postoperative use be undertaken with caution when hemostasis is critical (see WARNINGS and PRECAUTIONS ).
- Pediatrics and Tonsillectomy: Physicians should consider the increased risk of bleeding before deciding to administer TORADOL in patients following tonsillectomy. TORADOL IV/IM is not recommended for use in pediatric patients below the age of 2 years. In a retrospective analysis of patients having undergone tonsillectomy with or without adenoidectomy, the risk of bleeding was 10.1% in patients administered TORADOL IV/IM compared to 2.2% in those receiving opioids. The postoperative hemorrhage rate in patients 12 years and younger was 6.5% and 3.3% with and without TORADOL, respectively. In a prospective study of TORADOL in pediatric patients (ages 3 to 9 years) undergoing tonsillectomy with or without adenoidectomy, the overall incidence of bleeding was similar between the patients receiving TORADOL and morphine (16.3% versus 17%, respectively). However, during the first 24 hours after surgery, a higher incidence of bleeding was observed in the TORADOL IV/IM group (14.3%) versus the morphine group (4.2%).
- Anaphylactoid Reactions: Anaphylactoid reactions may occur in patients without a known previous exposure or hypersensitivity to aspirin, TORADOL or other NSAIDs, or in individuals with a history of angioedema, bronchospastic reactivity (eg, asthma) and nasal polyps. Anaphylactoid reactions, like anaphylaxis, may have a fatal outcome.
- Impaired Renal Function: TORADOL should be used with caution in patients with impaired renal function or a history of kidney disease because it is a potent inhibitor of prostaglandin synthesis. Renal toxicity with TORADOL has been seen in patients with conditions leading to a reduction in blood volume and/or renal blood flow where renal prostaglandins have a supportive role in the maintenance of renal perfusion. In these patients administration of TORADOL may cause a dose-dependent reduction in renal prostaglandin formation and may precipitate acute renal failure. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and the elderly. Discontinuation of TORADOL therapy is usually followed by recovery to the pretreatment state.
Renal Effects: TORADOL and its metabolites are eliminated primarily by the kidneys, which, in patients with reduced creatinine clearance, will result in diminished clearance of the drug (see CLINICAL PHARMACOLOGY ). Therefore, TORADOL should be used with caution in patients with impaired renal function (see DOSAGE AND ADMINISTRATION ) and such patients should be followed closely. With the use of TORADOL, there have been reports of acute renal failure, interstitial nephritis and nephrotic syndrome.
Because patients with underlying renal insufficiency are at increased risk of developing acute renal failure, the risks and benefits should be assessed prior to giving TORADOL to these patients. Hence, in patients with moderately elevated serum creatinine, it is recommended that the daily dose of TORADOL IV/IM be reduced by half, not to exceed 60 mg/day. TORADOL IS CONTRAINDICATED IN PATIENTS WITH SERUM CREATININE CONCENTRATIONS INDICATING ADVANCED RENAL IMPAIRMENT (see CONTRAINDICATIONS ).
Hypovolemia should be corrected before treatment with TORADOL is initiated.
- Fluid Retention and Edema: Fluid retention, edema, retention of NaCl, oliguria, elevations of serum urea nitrogen and creatinine have been reported in clinical trials with TORADOL. Therefore, TORADOL should be used only very cautiously in patients with cardiac decompensation, hypertension or similar conditions.
- Pregnancy: In late pregnancy, as with other NSAIDs, TORADOL should be avoided because it may cause premature closure of the ductus arteriosus.
· Hepatic Effects: TORADOL should be used with caution in patients with impaired hepatic function or a history of liver disease. Treatment with TORADOL may cause elevations of liver enzymes, and, in patients with pre-existing liver dysfunction, it may lead to the development of a more severe hepatic reaction. The administration of TORADOL should be discontinued in patients in whom an abnormal liver test has occurred as a result of TORADOL therapy.
· Hematologic Effects: TORADOL inhibits platelet aggregation and may prolong bleeding time; therefore, it is contraindicated as a preoperative medication, and caution should be used when hemostasis is critical. Unlike aspirin, the inhibition of platelet function by TORADOL disappears within 24 to 48 hours after the drug is discontinued. TORADOL does not appear to affect platelet count, prothrombin time (PT) or partial thromboplastin time (PTT). In controlled clinical studies, where TORADOL was administered intramuscularly or intravenously postoperatively, the incidence of clinically significant postoperative bleeding was 0.4% for TORADOL compared to 0.2% in the control groups receiving narcotic analgesics.
Information for Patients: TORADOL is a potent NSAID and may cause serious side effects such as gastrointestinal bleeding or kidney failure, which may result in hospitalization and even fatal outcome.
Physicians, when prescribing TORADOL, should inform their patients or their guardians of the potential risk of TORADOL treatment (see Boxed WARNING , WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS sections). Advise patients not to given TORADOL ORAL to other family members and to discard any unused drug.
Remember that the total duration of TORADOL therapy is not to exceed 5 days in adults or a single dose in pediatric patients ages 2 to 16 years.
Drug Interactions: Ketorolac is highly bound to human plasma protein (mean 99.2%).
Warfarin, Digoxin, Salicylate, and Heparin
The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 µg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that, at therapeutic concentrations of salicylate (300 µg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels. Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin and tolbutamide did not alter ketorolac tromethamine protein binding.
In a study involving 12 adult volunteers, TORADOL ORAL was coadministered with a single dose of 25 mg warfarin , causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin. In another study, TORADOL IV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo. Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored (see WARNINGS and PRECAUTIONS ).
TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 µg/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours. Therefore, concomitant use of TORADOL and probenecid is contraindicated.
Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs. The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of TORADOL on methotrexate clearance has not been studied.
Nondepolarizing Muscle Relaxants
In postmarketing experience there have been reports of a possible interaction between TORADOL IV/IM and nondepolarizing muscle relaxants that resulted in apnea. The concurrent use of TORADOL with muscle relaxants has not been formally studied.
Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
TORADOL IV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions. Do not mix TORADOL and morphine in the same syringe.
There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs.
Carcinogenesis, Mutagenesis and Impairment of Fertility: An 18-month study in mice with oral doses of ketorolac tromethamine at 2 mg/kg/day (0.9 times of human systemic exposure at the recommended IM or IV dose of 30 mg qid, based on area-under-the-plasma-concentration curve [AUC]), and a 24-month study in rats at 5 mg/kg/day (0.5 times the human AUC) showed no evidence of tumorigenicity.
Ketorolac tromethamine was not mutagenic in the Ames test, unscheduled DNA synthesis and repair, and in forward mutation assays. Ketorolac tromethamine did not cause chromosome breakage in the in vivo mouse micronucleus assay. At 1590 µg/mL and at higher concentrations, ketorolac tromethamine increased the incidence of chromosomal aberrations in Chinese hamster ovarian cells.
Impairment of fertility did not occur in male or female rats at oral doses of 9 mg/kg (0.9 times the human AUC) and 16 mg/kg (1.6 times the human AUC) of ketorolac tromethamine, respectively.
Pregnancy: Pregnancy Category C. Reproduction studies have been performed during organogenesis using daily oral doses of ketorolac tromethamine at 3.6 mg/kg (0.37 times the human AUC) in rabbits and at 10 mg/kg (1.0 times the human AUC) in rats. Results of these studies did not reveal evidence of teratogenicity to the fetus. Oral doses of ketorolac tromethamine at 1.5 mg/kg (0.14 times the human AUC), administered after gestation Day 17, caused dystocia and higher pup mortality in rats. There are no adequate and well-controlled studies of TORADOL in pregnant women. TORADOL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Labor and Delivery: The use of TORADOL is contraindicated in labor and delivery because, through its pro-staglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage (see CONTRAINDICATIONS ).
Lactation and Nursing: After a single administration of 10 mg of TORADOL ORAL to humans, the maximum milk concentration observed was 7.3 ng/mL, and the maximum milk-to-plasma ratio was 0.037. After 1 day of dosing (qid), the maximum milk concentration was 7.9 ng/mL, and the maximum milk-to-plasma ratio was 0.025. Because of the possible adverse effects of prostaglandin-inhibiting drugs on neonates, use in nursing mothers is contraindicated.
Pediatric Use: The safety and effectiveness of single doses of TORADOL IV/IM have been established in pediatric patients between the ages of 2 and 16 years. TORADOL IV/IM has been shown to be effective in the management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Safety and efficacy in pediatric patients below the age of 2 have not been established. Therefore, TORADOL IV/IM is not recommended in pediatric patients below the age of 2. The risk of bleeding was greater in those patients administered TORADOL IV/IM following tonsillectomy. Physicians should consider the increased risk of bleeding before deciding to administer TORADOL IV/IM in patients following tonsillectomy (see WARNINGS : Hemorrhage and Pediatrics and Tonsillectomy ).
The risks identified in the adult population with TORADOL IV/IM use also apply to pediatric patients. Therefore, consult the CONTRAINDICATIONS , WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS sections when prescribing TORADOL IV/IM to pediatric patients.
Geriatric Use (>/=65 years of age): Because ketorolac tromethamine may be cleared more slowly by the elderly (see CLINICAL PHARMACOLOGY ) who are also more sensitive to the adverse effects of NSAIDs (see WARNINGS : Renal Effects ), extra caution and reduced dosages (see DOSAGE AND ADMINISTRATION ) must be used when treating the elderly with TORADOL IV/IM . The lower end of the TORADOL IV/IM dosage range is recommended for patients over 65 years of age, and total daily dose is not to exceed 60 mg. The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with, TORADOL.
Adverse reaction rates increase with higher doses of TORADOL. Practitioners should be alert for the severe complications of treatment with TORADOL, such as GI ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see Boxed WARNING , WARNINGS , PRECAUTIONS , and DOSAGE AND ADMINISTRATION ). These NSAID-related complications can be serious in certain patients for whom TORADOL is indicated, especially when the drug is used inappropriately.
The Adverse Reactions Listed Below Were Reported in Clinical Trials as Probably Related to TORADOL:
- Incidence Greater Than 1%
Percentage of incidence in parentheses for those events reported in 3% or more patients.
Body as a Whole: edema (4%)
Dermatologic: pruritus, rash
Gastrointestinal: nausea (12%), dyspepsia (12%), gastrointestinal pain (13%), diarrhea (7%), constipation, flatulence, gastrointestinal fullness, vomiting, stomatitis
Hemic and Lymphatic: purpura
Nervous System: headache (17%), drowsiness (6%), dizziness (7%), sweating
Injection-site pain was reported by 2% of patients in multidose studies.
- Incidence 1% or Less
Body as a Whole: weight gain, fever, infections, asthenia
Cardiovascular: palpitation, pallor, syncope
Gastrointestinal: gastritis, rectal bleeding, eructation, anorexia, increased appetite
Hemic and Lymphatic: epistaxis, anemia, eosinophilia
Nervous System: tremors, abnormal dreams, hallucinations, euphoria, extrapyramidal symptoms, vertigo, paresthesia, depression, insomnia, nervousness, excessive thirst, dry mouth, abnormal thinking, inability to concentrate, hyperkinesis, stupor
Respiratory: dyspnea, pulmonary edema, rhinitis, cough
Special Senses: abnormal taste, abnormal vision, blurred vision, tinnitus, hearing loss
Urogenital: hematuria, proteinuria, oliguria, urinary retention, polyuria, increased urinary frequency
The Following Adverse Events Were Reported From Postmarketing Experience:
Cardiovascular: hypotension, flushing
Dermatologic: Lyell's syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, maculopapular rash, urticaria
Hepatic: hepatitis, liver failure, cholestatic jaundice
Nervous System: convulsions, psychosis, aseptic meningitis
Respiratory: asthma, bronchospasm
Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.
Patients should be managed by symptomatic and supportive care following a NSAIDs overdose. There are no specific antidotes. Emesis and/or activated charcoal (60 g to 100 g in adults, 1 g/kg to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large oral overdose (5 to 10 times the usual dose).
In controlled overdosage, daily doses of 360 mg of TORADOL IV/IM given for 5 days (three times the highest recommended dose), caused abdominal pain and peptic ulcers which healed after discontinuation of dosing. Metabolic acidosis has been reported following intentional overdosage.
Single overdoses of TORADOL have been variously associated with abdominal pain, nausea, vomiting, hyperventilation, peptic ulcers and/or erosive gastritis and renal dysfunction which have resolved after discontinuation of dosing. Dialysis does not significantly clear ketorolac tromethamine from the blood stream.
Dosage and Administration
IN ADULTS, THE COMBINED DURATION OF USE OF TORADOL IV/IM AND TORADOL ORAL IS NOT TO EXCEED 5 DAYS. IN ADULTS, THE USE OF TORADOL ORAL IS ONLY INDICATED AS CONTINUATION THERAPY TO TORADOL IV/IM .
Adults Patients: TORADOL IV/IM may be used as a single or multiple dose on a regular or prn schedule for the management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Hypovolemia should be corrected prior to the administration of TORADOL (see WARNINGS : Renal Effects ). Patients should be switched to alternative analgesics as soon as possible, but TORADOL therapy is not to exceed 5 days.
When administering TORADOL IV/IM , the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins in ~30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM, Duration of analgesic effect is usually 4 to 6 hours.
Single-Dose Treatment: The Following Regimen Should Be Limited to Single Administration Use Only
- Patients <65 years of age: One dose of 60 mg.
- Patients >/=65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: One dose of 30 mg.
- Patients <65 years of age: One dose of 30 mg.
- Patients >/=65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: One dose of 15 mg.
Pediatric Patients (2 to 16 years of age): The pediatric population should receive only a single dose of TORADOL injection, as follows:
- One dose of 1 mg/kg up to a maximum of 30 mg.
- One dose of 0.5 mg/kg up to a maximum of 15 mg.
Multiple-Dose Treatment (IV or IM) in Adults
- Patients <65 years of age: The recommended dose is 30 mg TORADOL IV/IM every 6 hours. The maximum daily dose should not exceed 120 mg.
- For Patients >/=65 years of age, renally impaired patients (see WARNINGS ) and patients less than 50 kg (110 lbs): The recommended dose is 15 mg TORADOL IV/IM every 6 hours. The maximum daily dose for these populations should not exceed 60 mg.
For breakthrough pain do not increase the dose or the frequency of TORADOL. Consideration should be given to supplementing these regimens with low doses of opioids prn unless otherwise contraindicated.
Pharmaceutical Information for TORADOL IV/IM : Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
TORADOL IV/IM should not be mixed in a small volume (eg, in a syringe) with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride or hydroxyzine hydrochloride; this will result in precipitation of ketorolac from solution.
TORADOL ORAL is indicated ONLY as continuation therapy to TORADOL IV/IM for the management of moderately severe acute pain that requires analgesia at the opioid level (see also PRECAUTIONS : Information for Patients ).
Transition From TORADOL IV/IM to TORADOL ORAL in Adults: The recommended TORADOL ORAL dose is as follows:
- Adult Patients <65 years of age: 2 tablets as a first oral dose for patients who received 60 mg IM single dose, 30 mg IV single dose or 30 multiple dose. TORADOL IV/IM followed by 1 tablet TORADOL ORAL every 4 to 6 hours, not to exceed 40 mg/24 h of TORADOL ORAL .
- Patients >/=65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: 1 tablet as a first oral dose for patients who received 30 mg IM single dose, 15 mg IV single dose or 15 mg multiple dose. TORADOL IV/IM followed by 1 tablet TORADOL ORAL every 4 to 6 hours, not to exceed 40 mg/24 h of TORADOL ORAL .
Shortening the recommended dosing intervals may result in increased frequency and severity of adverse reactions.
In adults, the maximum combined duration of use (parenteral and oral TORADOL is limited to 5 days.
TORADOL IV/IM for intramuscular or intravenous use is available in a sterile vial:
15 mg: 15 mg/mL, 1 mL fill per 2 mL single use vial, box of 10 (NDC 0004-6925-06).
30 mg: 30 mg/mL, 1 mL fill per 2 mL single use vial, box of 10 (NDC 0004-6926-06).
For IM Single-Dose Use Only; Not Intended for IV Use -- 60 mg: 30 mg/mL, 2 mL fill per 2 mL single use vial, box of 1 (NDC 0004-6927-09).
Store vials at 15° to 30°C (59° to 86°F) with protection from light.
TORADOL ORAL 10 mg tablets are round, white, film-coated, red printed tablets. There is a large T printed on both sides of the tablet, with TORADOL on one side, and ROCHE on the other, available in bottles of 100 tablets (NDC 0004-0273-01).
Store bottles at 15° to 30°C (59° to 86°F).
Revised: September 2002
PRODUCT PHOTO(S):NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.
The product samples shown here have been supplied by the manufacturer. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug's identity should be verified by chemical analysis.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.